SARS-CoV-2 emerged at the end of 2019 as the cause of COVID-19 resulting in a pandemic. Data from observational studies indicate that a subset of people with HIV are at increased risk of severe COVID-19 outcomes. Opportunities should not be missed to offer immunisation against SARS-CoV-2 to people with HIV. Numerous vaccine candidates are in development and several have received authorisation in the UK and worldwide, although there is limited information that is specific to people with HIV.
These guidelines aim to provide information for healthcare professionals on the use of SARS-CoV-2 immunisation in people with HIV. They are based on the interpretation of current evidence, and will be kept under review and updated as new evidence emerges.
This consultation will be open for 1 month until 5.00 pm on Friday 23 April 2021.
Non-technical summary in development.
Please leave feedback via the form below.